Pak Fah Yeow International Limited Overview
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Employees at year end (number) | 87 | 95 | 102 | 106 | 100 |
| Staff costs (HK$ M) | 34.6 | 34.6 | 44.0 | 43.3 | 45.6 |
| Revenue per employee (HK$ M) | 1.61 | 1.55 | 2.54 | 2.23 | 2.14 |
Source: Annual results announcements FY2022, FY2024, FY2025 (Employees and Remuneration Policies; Consolidated Statement of Comprehensive Income). Revenue per employee is analyst-derived.
Pak Fah Yeow International is a family-controlled Hong Kong heritage consumer-health company whose economic engine is a single nearly century-old brand: Hoe Hin White Flower Embrocation (白花油, "Pak Fah Yeow"), a eucalyptus-, lavender-, menthol- and methyl salicylate-based medicated oil used for headaches, congestion, motion sickness, muscular pain and insect bites. Healthcare generated 92.3% of FY2025 revenue at a segment margin near 59%, giving the group exceptionally high-margin, asset-light-like economics despite owning its manufacturing. Around this brand sit two capital-allocation businesses — an HK$228 million investment-property portfolio across Hong Kong, Singapore and the United Kingdom, and a treasury book of roughly HK$350 million in cash and securities. The group is effectively debt-free, pays out 60–80% of earnings, and trades near book value. Its strategic challenge is demographic and channel-related: renewing a legacy brand for younger, online-first Chinese consumers while managing heavy dependence on Greater China and on five distributors.
What the company does
Pak Fah Yeow International is an investment holding company organised into three reportable operating segments, as defined in note 2 of the FY2025 annual results announcement:
-
Healthcare — manufacture and sale of Hoe Hin brand of products.
-
Property Investments — rental of investment properties in Hong Kong (office and residential), Singapore (industrial) and the United Kingdom (retail/residential).
-
Treasury Investments — bank deposits, equity and debt securities, mutual funds and dual-currency investments.
Company's own description
In its annual reports, the company describes itself as principally engaged in the manufacture, marketing and distribution of healthcare products under its Hoe Hin brand, centred on the medicated oil known as Pak Fah Yeow, with manufacturing carried out by its subsidiary Hoe Hin Pak Fah Yeow Manufactory Limited, and with supplementary property and treasury investment activities (Annual Report 2022 and 2023, "About Us"). The 2022 report described the oil as having been manufactured for over 95 years and sold in Hong Kong, Macau, Mainland China, Southeast Asia and western countries.
Revenue model
| Revenue type (FY2025) | HKD Mn | % of revenue | Nature |
|---|---|---|---|
| Sale of Hoe Hin products — fixed price | 75.2 | 35.2 | Product sales (HKFRS 15) |
| Sale of Hoe Hin products — variable price | 122.1 | 57.1 | Product sales with rebates/discounts to distributors (HKFRS 15) |
| Lease income (fixed lease payments) | 9.9 | 4.6 | Rental (HKFRS 16) |
| Interest income from bank deposits | 6.6 | 3.1 | Treasury |
| Total revenue | 213.9 | 100.0 | — |
Source: FY2025 Annual Results Announcement, note 3. The business is almost entirely a branded-product model; there is no subscription, licensing or service revenue of significance. The variable-price share of product revenue rose from 46.4% in FY2024 to 61.9% in FY2025, reflecting heavier use of distributor rebate and discount arrangements.
Value chain position
The group is vertically integrated from formulation to finished packaged product: it sources essential oils and actives (retail product listings state that most natural ingredients are imported from France, China and Australia to British Pharmacopoeia or Chinese Pharmacopoeia standards), manufactures and bottles in Hong Kong, and sells primarily to distributors and chain retailers. It does not operate its own retail stores. In Hong Kong its core channels are drug stores and major chain retailers (FY2025 MD&A); product listings confirm presence at Watsons and Mannings. In Mainland China, the company is building direct-to-consumer reach through Douyin and Xiaohongshu content marketing, KOL partnerships and cross-border e-commerce launched in 2025.
Customer types and concentration
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue from customers each above 10% of healthcare revenue (HK$ M) | 112.9 | 85.7 | 133.8 | 124.6 | 147.0 |
| Number of such customers | 6 | 4 | 4 | 4 | 5 |
| Share of healthcare segment revenue (%) | 84.9 | 61.5 | 54.6 | 57.3 | 74.5 |
Customers are predominantly distributors and retail chains. Concentration is high and rising:
Source: Annual results announcements FY2022, FY2024, FY2025 ("Information about major customers"). Percentages analyst-derived.
End-markets served
Over-the-counter (OTC) topical analgesic and traditional medicated oil category, primarily in Greater China (Hong Kong, Macau, Mainland China), Southeast Asia (notably the Philippines, Singapore, Thailand, Malaysia), and North America (United States, Canada), with minor sales elsewhere. The product is registered in Hong Kong as a proprietary Chinese medicine (Hong Kong Memory Project oral history).
Independent characterisation
Pak Fah Yeow is best understood as a single-brand heritage consumer-health franchise wrapped in a family holding company. The franchise earns segment margins of 59–64% and requires minimal capital expenditure (additions to non-current assets of only HK$0.4 million in FY2025). Surplus cash is not reinvested in growth M&A — management has repeatedly stated it has no plan for significant investment or acquisition of capital assets — but retained in deposits, securities and property, or distributed as special dividends. The result is a business whose reported earnings are distorted by non-cash property revaluations, whose balance sheet is over-capitalised (cash and securities equal roughly half of market capitalisation), and whose growth is driven by cyclical swings in Greater China demand rather than structural expansion. The 2023 border-reopening boom (healthcare revenue +75.8%) followed by a two-year normalisation illustrates the volatility.
Strategy
Stated strategic themes (paraphrased from FY2024 and FY2025 Chairman's Statements and H1 2026 MD&A)
-
Digital transformation of China distribution: Shift resources toward e-commerce and online engagement in China to match consumer migration online; FY2024 disclosed that online contributed less than 3% of revenue, a gap management is explicitly trying to close.
-
Content and KOL marketing: Increase advertising on Douyin and Xiaohongshu, collaborate with key opinion leaders, and enhance video content to rebuild brand visibility among younger consumers.
-
Cross-border e-commerce: Launched in 2025 to diversify channels; management cautioned that these initiatives may take time to contribute meaningfully.
-
Product portfolio extension: Planned launch of Hoe Hin White Flower Oil Roll-On and GoodDay essential oil to attract new consumer groups (H1 2026).
-
Centenary brand campaign: Advertising and promotional campaigns prepared for the 100th anniversary (1927–2027).
-
Southeast Asia brand building: Continued branding and promotion in the Philippines, Singapore and Thailand.
-
Prudent asset management: Maintain occupancy and rental stability across the property portfolio amid Hong Kong vacancy pressure.
-
Conservative treasury: Prioritise capital preservation while seeking reasonable risk-adjusted returns.
-
Shareholder returns: Sustain regular plus special dividends; maintain a strong balance sheet and liquidity.
Initiatives announced in the last 24 months
| Initiative | Announced | Status | Targets disclosed |
|---|---|---|---|
| Expanded online promotion and e-commerce focus in China | Mar 2025 (FY2024 results) | In progress | None quantified |
| Douyin / Xiaohongshu / KOL / video content programme | FY2025 | Ongoing | None quantified |
| Cross-border e-commerce operations | Launched during 2025 | Operating; early stage | — |
| Advertising cost discipline (spend cut to HK$10.2 million from HK$14.1 million) | FY2025 | Completed | — |
| 100th-anniversary advertising campaigns | H1 2026 | Prepared, rolling out | — |
| White Flower Oil Roll-On | Aug 2026 | Planned launch | — |
| GoodDay essential oil | Aug 2026 | Planned launch | — |
| Thailand product licence renewal (with possible packaging changes) | H1 2026 disclosure | Scheduled Q4 2026 | — |
| Generational transfer of Hexagan | 30 Jun 2026 | Completed | — |
ESG commitments
Energy-efficiency optimisation, a comprehensive recycling programme and improved packaging materials to reduce environmental footprint (FY2024 Chairman's Statement). Annual ESG reports published alongside annual reports. No quantified emissions targets were found.
Medium-term targets and guidance
Management does not issue quantitative financial targets or guidance. Qualitative H2 2026 outlook: cautious; China improvement encouraging but sustainability uncertain; deferred Philippine orders expected in H2; US orders expected to resume; full-year North American revenue expected to remain broadly stable.
Products & Services
The company does not publish a SKU-level catalogue, revenue by product, or prices in its filings. The list below is compiled from filings, regulatory product labels and retailer listings. All products sit within the Healthcare segment under the Hoe Hin brand.
Healthcare segment
Hoe Hin White Flower Embrocation (白花油 / Pak Fah Yeow) — flagship
-
Description: A blend of essential oils including eucalyptus oil and lavender oil, with methyl salicylate and menthol (retailer listings; some listings also cite camphor and wintergreen oil).
-
Indications (per retail labelling): relief of congestion associated with colds, dizziness and headache, temporary muscular pain, travel and motion sickness, and itching from insect bites; also used as a refreshing inhalant.
-
Regulatory status: registered in Hong Kong as a proprietary Chinese medicine (HK Memory oral history).
-
Formats: bottles in multiple sizes (e.g., 5ml listed in Malaysia; 10ml "#2" listed at Watsons Hong Kong at around HK$47).
-
Target customer: mass-market households in Greater China and Southeast Asia, historically skewing to older consumers; overseas Chinese diaspora in North America.
-
Launch year: 1927; formula kept largely unchanged to preserve its characteristic scent (HK Memory oral history).
-
Pricing model: retail price per bottle through distributors and chain retailers; distributor pricing increasingly on variable terms with rebates (61.9% of FY2025 product revenue was variable-price).
Hoe Hin White Flower Embrocation Floral-Scented "Fuzai 239" (福仔239)
-
Description: The traditional formula with added floral fragrance, developed to offer an alternative scent (retailer listing).
-
Indications: as for the flagship, including cooling and relief of summer heat.
-
Format: 10ml; listed at Mannings Hong Kong at around HK$46–50.
-
Target customer: consumers deterred by the pungency of traditional medicated oils; younger and female consumers.
-
Launch year: not publicly disclosed. The name echoes the company's stock code 239.
White Flower Strain Relief Pain Relieving Oil
-
Description: OTC external analgesic oil with camphor 10%, menthol 15% and methyl salicylate approximately 48–50% (US FDA OTC label records).
-
Indications: temporary relief of minor aches and pains of muscles and joints (backache, arthritis, strains, bruises, sprains).
-
Format: 50ml (1.7 fl oz) under NDC 48256-0041-1; label revised October 2023.
-
Target customer: North American OTC pain-relief consumers.
-
Labeler/manufacturer: Hoe Hin Pak Fah Yeow Manufactory Ltd.
Hoe Hin White Flower ointment
-
Description: Ointment format of the White Flower brand; historically advertised alongside the oil (1983 advertisement in HK Memory archive; Yahoo Finance company profile references ointments).
-
Specifications, launch year and pricing: not publicly disclosed.
Hoe Hin White Flower Oil Roll-On (planned)
-
Description: Roll-on applicator format announced in the H1 2026 outlook as a planned launch.
-
Target: new consumer groups seeking convenient, less messy application.
-
Launch: planned, timing not specified (Interim Results 2026).
GoodDay essential oil (planned)
-
Description: New essential-oil product announced in the H1 2026 outlook to broaden the portfolio.
-
Target: new consumer groups; positioning appears to extend beyond medicated oils into wellness aromatherapy (analyst inference).
-
Launch: planned, timing not specified (Interim Results 2026).
Advertising agency services
- Yahoo Finance's company profile lists advertising agency services among group activities; this is not separately disclosed in segment reporting and appears to be an in-house function.
Property Investments segment
| Asset | Type | Valuation 31 Dec 2025 (original currency) | Valuation (HKD Mn) | FY2025 rent (HKD Mn) | Occupancy FY2025 |
|---|---|---|---|---|---|
| Hong Kong portfolio | Office and residential | HK$102.09 million | 102.1 | 3.4 | 100% |
| Singapore portfolio | Industrial | S$2.434 million | 14.7 | 0.3 | 100% |
| United Kingdom portfolio | Retail/residential (retail tenants include a multinational fast-food chain secured in 2022) | GBP10.66 million | 111.7 | 6.2 | 100% |
Source: FY2025 Annual Results Announcement; FY2022 Chairman's Statement.
Treasury Investments segment
Bank deposits (HK$331.3 million cash and bank balances at end-FY2025; HK$377.4 million at 30 June 2026), listed equity and debt securities and mutual funds held at fair value through profit or loss (HK$18.1 million at end-FY2025; HK$27.7 million at 30 June 2026), and dual-currency investments.
Financial Narrative
All figures HK$ M, fiscal years ending 31 December. Sources: FY2022, FY2024, FY2025 Annual Results Announcements (audited). Derived metrics are labelled.
Income statement
Derivations: Gross profit = revenue less raw materials and consumables used and changes in inventories of finished goods (excludes production labour and overheads, so it overstates a conventional gross margin). EBITDA = profit from operations before fair value changes plus depreciation; note it includes treasury interest income because the company reports interest as revenue.
Per-share data (HK cents)
Diluted equals basic; there are no dilutive instruments. Weighted shares were 311.64 million in every year.
Margins (%)
Revenue CAGR FY2021–FY2025: 11.2% (HK$139.8 million to HK$213.9 million). Healthcare revenue CAGR: 10.4%. Underlying recurring profit CAGR: 28.4%. These CAGRs are flattered by the depressed COVID-era FY2021 base; FY2023–FY2025 revenue declined at a compound rate of 9.2% a year.
Commentary on the income statement. Three phases are visible. (1) FY2021–FY2022: COVID-constrained recovery, with revenue near HK$140–147 million and operating margins near 32–33%. (2) FY2023: an exceptional surge as the Hong Kong–Mainland border reopened, travellers resumed buying in Hong Kong and Macau, and a wave of purchasing occurred in China; revenue rose 76.1% and operating margin jumped to 55.4%. (3) FY2024–FY2025: normalisation, with China healthcare revenue down 17.2% and then 11.4%, though management said FY2025 Mainland sales met the original full-year target. Through this decline the group protected margins: advertising was cut 28% in FY2025 (HK$14.1 million to HK$10.2 million), helping keep EBITDA margin flat at 55.2%. The divergence between underlying recurring profit and reported profit is driven by property revaluations: cumulative investment-property fair value losses over FY2022–FY2025 were HK$55.6 million, plus a further HK$97.6 million of OCI revaluation deficits on self-use properties in FY2024–FY2025. The lower FY2025 effective tax rate (15.0% vs 19.6%) reflects smaller non-deductible revaluation losses.
Balance sheet
Net debt = bank borrowings less cash and bank balances (excludes FVPL securities and trademark payable). The nature of the long-term deferred income balance (HK$43.4 million at end-FY2025) is not explained in the results announcements and should be checked against the full annual report.
At 30 June 2026 (unaudited): total assets HK$878.3 million; cash HK$377.4 million; FVPL HK$27.7 million; bank borrowings HK$4.9 million; dividends payable HK$35.3 million; equity HK$734.0 million; NAV per share HK$2.36 (Interim Results 2026).
Commentary. The balance sheet is conservatively, arguably excessively, capitalised. Cash rose for four consecutive years to HK$331 million (40% of total assets) despite record dividend payouts. Gearing has been below 1% since FY2022, after management repaid most of its GBP loan in H2 2022 in anticipation of rate rises. Equity has been flat around HK$707–765 million for five years because special dividends and OCI property write-downs have offset retained earnings.
Cash flow
FY2025 capex (additions to non-current assets) was HK$0.4 million. The FY2025 increase in cash of HK$55.4 million despite roughly HK$57.7 million of dividends paid implies operating cash generation above HK$100 million (analyst inference, not a reported figure).
Dividends paid derived as prior-year final and special dividends approved and paid during the year plus current-year interim dividends (dividend notes, FY2022, FY2024, FY2025). No shares were purchased, sold or redeemed in any year reviewed.
Ratios
Derivation notes: ROIC = operating profit before fair value changes × (1 − effective tax rate) ÷ (equity + bank borrowings − cash); this includes interest income in the numerator, overstating operating ROIC slightly. Inventory and payable days use cost of inventories; receivable days use trade plus bills receivables over healthcare revenue. Current ratio, gearing and interest coverage are as reported by the company.
Commentary on ratios. Reported ROE of 10–14% understates the franchise's economic returns because roughly 40–45% of equity sits in low-yielding cash and property. Stripping out cash, invested-capital returns exceed 20%. The cash conversion cycle of about 120 days is long for a consumer product, driven by roughly three months of inventory (reflecting batch manufacturing and imported raw materials) and 30–120-day distributor credit terms. Receivable days rose to 48 in FY2024 as a larger share of sales went through credit-term distributors, then eased to 40 in FY2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/services |
|---|---|---|
Healthcare | Manufacture and sale of Hoe Hin brand of products via Hoe Hin Pak Fah Yeow Manufactory Limited | White Flower Embrocation (various sizes), floral-scented Fuzai 239, Strain Relief pain-relieving oil, ointment; new roll-on and GoodDay essential oil planned |
Property Investments | Investment properties held for rental | Hong Kong office and residential; Singapore industrial; UK retail/residential |
Treasury Investments | Deposits and financial assets | Bank deposits, listed equity and debt securities, mutual funds, dual-currency investments |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare revenue (HKD Mn) | 133.0 | 139.5 | 245.2 | 217.4 | 197.3 |
Property Investments revenue (HKD Mn) | 6.8 | 7.1 | 9.6 | 9.1 | 9.9 |
Treasury Investments revenue (HKD Mn) | 0.0 | 0.6 | 4.4 | 10.3 | 6.6 |
Total revenue (HKD Mn) | 139.8 | 147.2 | 259.2 | 236.8 | 213.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare segment result (HKD Mn) | 54.4 | 57.4 | 150.6 | 127.8 | 116.8 |
Property segment result reported (HKD Mn) | 6.4 | -3.8 | -7.1 | -18.5 | 2.1 |
Property underlying recurring result (HKD Mn) | 5.4 | 4.0 | 8.3 | 7.6 | 8.5 |
Treasury segment result reported (HKD Mn) | 1.3 | -0.3 | 5.5 | 9.5 | 11.4 |
Treasury underlying recurring result (HKD Mn) | -0.6 | 2.1 | 4.2 | 8.5 | 9.2 |
Unallocated corporate expenses (HKD Mn) | -14.6 | -14.8 | -19.6 | -20.4 | -22.2 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare segment margin (%) | 40.9 | 41.1 | 61.4 | 58.8 | 59.2 |
Property underlying margin (%) | 79.1 | 56.4 | 85.9 | 83.0 | 85.3 |
Healthcare revenue YoY growth (%) | 0.0 | 4.9 | 75.8 | -11.3 | -9.2 |
Property revenue YoY growth (%) | 0.0 | 5.2 | 34.8 | -5.2 | 9.0 |
Healthcare share of revenue (%) | 95.1 | 94.7 | 94.6 | 91.8 | 92.3 |
Property share of revenue (%) | 4.8 | 4.8 | 3.7 | 3.8 | 4.6 |
Treasury share of revenue (%) | 0.0 | 0.4 | 1.7 | 4.3 | 3.1 |
Segment Assets & Liabilities
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Healthcare segment assets (HKD Mn) | 472.5 | 489.7 | 441.7 | 360.3 | 312.8 |
Property segment assets (HKD Mn) | 287.4 | 266.3 | 257.0 | 228.2 | 229.8 |
Treasury segment assets (HKD Mn) | 76.0 | 65.7 | 206.7 | 248.6 | 279.2 |
Revenue by Segment (Half-Yearly)
| Segment | H1 2022 | H1 2023 | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|---|---|
Healthcare revenue (HKD Mn) | 53.1 | 120.9 | 123.4 | 86.7 | 93.6 |
Group revenue (HKD Mn) | 56.2 | 126.4 | 132.5 | 94.7 | 101.0 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 139.8 | 147.2 | 259.2 | 236.8 | 213.9 |
Raw materials and inventory change (HKD Mn) | 29.3 | 31.0 | 40.3 | 32.6 | 29.3 |
Gross profit, derived (HKD Mn) | 110.5 | 116.2 | 218.9 | 204.1 | 184.6 |
Staff costs (HKD Mn) | 34.6 | 34.6 | 44.0 | 43.3 | 45.6 |
Other operating expenses (HKD Mn) | 23.7 | 27.8 | 24.4 | 28.2 | 23.6 |
of which advertising, promotion and events (HKD Mn) | 12.0 | 13.2 | 10.8 | 14.1 | 10.2 |
Depreciation (HKD Mn) | 7.2 | 7.5 | 7.4 | 7.4 | 5.8 |
Operating profit before fair value changes (HKD Mn) | 44.5 | 48.7 | 143.5 | 123.3 | 112.3 |
EBITDA, derived (HKD Mn) | 51.7 | 56.2 | 150.8 | 130.7 | 118.1 |
Fair value change on investment properties (HKD Mn) | 1.0 | -7.8 | -15.4 | -26.0 | -6.3 |
Fair value change on financial assets (HKD Mn) | 2.0 | -2.5 | 1.3 | 1.1 | 2.1 |
Profit from operations (HKD Mn) | 47.5 | 38.4 | 129.4 | 98.3 | 108.1 |
Finance costs (HKD Mn) | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 |
Pre-tax income (HKD Mn) | 46.9 | 37.8 | 128.8 | 97.8 | 107.5 |
Taxation (HKD Mn) | 8.7 | 7.8 | 23.8 | 19.1 | 16.2 |
Net income attributable (HKD Mn) | 38.2 | 30.0 | 105.0 | 78.6 | 91.3 |
Underlying recurring profit (HKD Mn) | 35.2 | 40.2 | 119.1 | 103.6 | 95.5 |
Total comprehensive income (HKD Mn) | 55.1 | 24.1 | 105.6 | 33.7 | 48.5 |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic, reported (HK cents) | 12.3 | 9.6 | 33.7 | 25.2 | 29.3 |
EPS diluted, reported (HK cents) | 12.3 | 9.6 | 33.7 | 25.2 | 29.3 |
EPS underlying recurring (HK cents) | 11.3 | 12.9 | 38.2 | 33.2 | 30.7 |
Dividends per share total (HK cents) | 8.4 | 9.1 | 20.5 | 20.0 | 19.0 |
Net asset value per share (HKD) | 2.27 | 2.27 | 2.46 | 2.35 | 2.32 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, derived (%) | 79.0 | 78.9 | 84.5 | 86.2 | 86.3 |
Operating margin before FV changes (%) | 31.9 | 33.1 | 55.4 | 52.1 | 52.5 |
EBITDA margin (%) | 37.0 | 38.2 | 58.2 | 55.2 | 55.2 |
Pre-tax margin (%) | 33.6 | 25.7 | 49.7 | 41.3 | 50.3 |
Net margin (%) | 27.3 | 20.3 | 40.5 | 33.2 | 42.7 |
Underlying recurring profit margin (%) | 25.2 | 27.3 | 45.9 | 43.8 | 44.7 |
Effective tax rate (%) | 18.6 | 20.7 | 18.5 | 19.6 | 15.0 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 837.7 | 823.1 | 907.5 | 843.4 | 828.4 |
Investment properties (HKD Mn) | 285.6 | 264.9 | 255.3 | 227.0 | 228.5 |
Property, plant and equipment (HKD Mn) | 337.1 | 336.2 | 326.6 | 268.7 | 203.1 |
Cash and bank balances (HKD Mn) | 164.7 | 169.4 | 265.5 | 275.8 | 331.3 |
Financial assets at FVPL, total (HKD Mn) | 18.7 | 15.9 | 17.0 | 19.1 | 18.1 |
Inventories (HKD Mn) | 15.1 | 15.8 | 12.2 | 12.1 | 12.6 |
Trade and other receivables (HKD Mn) | 13.0 | 17.5 | 27.5 | 33.2 | 27.2 |
Short-term debt, secured bank borrowings (HKD Mn) | 16.2 | 5.5 | 4.7 | 4.2 | 4.8 |
Long-term debt (HKD Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Trademark consideration payable, long-term (HKD Mn) | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
Net debt, negative = net cash (HKD Mn) | -148.5 | -163.9 | -260.8 | -271.6 | -326.5 |
Goodwill (HKD Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Intangible assets (HKD Mn) | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
Working capital, net current assets (HKD Mn) | 174.7 | 193.9 | 273.1 | 318.4 | 367.3 |
Deferred income, total (HKD Mn) | 39.1 | 37.0 | 39.3 | 40.0 | 43.7 |
Deferred tax liabilities (HKD Mn) | 51.2 | 52.0 | 51.0 | 42.3 | 32.2 |
Total liabilities (HKD Mn) | 130.0 | 115.9 | 142.3 | 111.4 | 105.6 |
Shareholders' equity (HKD Mn) | 707.7 | 707.2 | 765.2 | 731.9 | 722.7 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Operating cash flow, third-party data (HKD Mn) | 70.4 | 39.9 | 147.9 | 79.0 |
Capex, additions to non-current assets (HKD Mn) | 0.8 | 0.2 | 3.1 | 0.9 |
Free cash flow, derived (HKD Mn) | 69.6 | 39.7 | 144.8 | 78.1 |
Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid in year, derived (HKD Mn) | 20.6 | 24.6 | 47.7 | 67.0 | 57.7 |
Dividends declared for the year (HKD Mn) | 26.2 | 28.4 | 63.9 | 62.3 | 59.2 |
Share buybacks (HKD Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, on year-end equity (%) | 5.4 | 4.2 | 13.7 | 10.7 | 12.6 |
ROE on underlying profit (%) | 5.0 | 5.7 | 15.6 | 14.2 | 13.2 |
ROA (%) | 4.6 | 3.6 | 11.6 | 9.3 | 11.0 |
ROIC, derived (%) | 6.5 | 7.1 | 23.2 | 21.5 | 24.1 |
Current ratio (x) | 6.5 | 10.8 | 7.2 | 16.2 | 18.4 |
Debt to equity (%) | 2.3 | 0.8 | 0.6 | 0.6 | 0.7 |
Net debt to EBITDA (x) | -2.9 | -2.9 | -1.7 | -2.1 | -2.8 |
Interest coverage, company definition (x) | 78.6 | 75.6 | 233.3 | 211.2 | 205.6 |
Asset turnover (x) | 0.17 | 0.18 | 0.29 | 0.28 | 0.26 |
Inventory days, derived | 117 | 119 | 74 | 83 | 91 |
Receivable days, derived | 24 | 35 | 34 | 48 | 40 |
Payable days, derived | 13 | 7 | 9 | 10 | 13 |
Cash conversion cycle, derived (days) | 128 | 147 | 99 | 121 | 118 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
China incl. Hong Kong and Macau (HKD Mn) | 97.6 | 101.4 | 202.7 | 167.8 | 148.6 |
Southeast Asia (HKD Mn) | 24.1 | 26.3 | 34.1 | 36.6 | 35.4 |
North America (HKD Mn) | 10.5 | 10.4 | 7.3 | 11.5 | 11.9 |
Others (HKD Mn) | 0.8 | 1.4 | 1.1 | 1.5 | 1.4 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
China growth (%) | 3.9 | 99.9 | -17.2 | -11.4 |
Southeast Asia growth (%) | 9.1 | 29.4 | 7.3 | -3.2 |
North America growth (%) | -1.4 | -29.6 | 58.3 | 3.2 |
Others growth (%) | 76.4 | -22.0 | 35.0 | -3.0 |
Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
China share of healthcare revenue (%) | 73.4 | 72.7 | 82.7 | 77.2 | 75.3 |
Southeast Asia share (%) | 18.1 | 18.9 | 13.9 | 16.8 | 17.9 |
North America share (%) | 7.9 | 7.4 | 3.0 | 5.3 | 6.0 |
Others share (%) | 0.6 | 1.0 | 0.4 | 0.7 | 0.7 |
Revenue by Region — China revenue
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
China revenue (HKD Mn) | 101.2 | 105.7 | 210.2 | 179.0 | 157.3 |
Southeast Asia revenue (HKD Mn) | 24.4 | 26.7 | 35.1 | 38.2 | 36.9 |
North America revenue (HKD Mn) | 10.5 | 10.4 | 7.3 | 11.9 | 11.9 |
United Kingdom revenue (HKD Mn) | 3.0 | 3.1 | 5.5 | 6.1 | 6.4 |
Other regions revenue (HKD Mn) | 0.8 | 1.4 | 1.1 | 1.5 | 1.4 |
China operating result (HKD Mn) | 38.2 | 35.1 | 125.9 | 83.1 | 86.8 |
Southeast Asia operating result (HKD Mn) | 11.7 | 11.8 | 19.7 | 21.2 | 26.5 |
North America operating result (HKD Mn) | 4.4 | 4.2 | 3.6 | 6.4 | 5.8 |
United Kingdom operating result (HKD Mn) | 3.7 | -1.5 | -3.4 | 3.6 | 7.0 |
Locations
| Location | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong office and residential (HKD Mn) | 3.6 | 3.9 | 4.0 | 3.2 | 3.4 |
Singapore industrial (HKD Mn) | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 |
United Kingdom retail/residential (HKD Mn) | 3.0 | 3.1 | 5.3 | 5.6 | 6.2 |
Revenue by Region (Half-Yearly)
| Region | H1 2025 | H1 2026 |
|---|---|---|
China (HKD Mn) | 67.7 | 80.3 |
Southeast Asia (HKD Mn) | 18.0 | 13.2 |
North America (HKD Mn) | 0.9 | 0.0 |
Others (HKD Mn) | 0.2 | 0.1 |
Share Price History
| Date | Price (HKD) | Source |
|---|---|---|
26 Apr 2024 | about 2.07–2.12 (52-week range 1.24–2.20) | Yahoo Finance |
25 Jul 2025 | 2.47 | Stoxray |
5 Dec 2025 | 2.43 | Stoxray |
27 Feb 2026 | 2.42 | ET Net |
20 Jul 2026 | 2.32 (52-week range 2.24–2.55) | Google Finance |
31 Jul 2026 | 2.31 | StockAnalysis |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalisation | HK$720 million | 311.64 million shares × HK$2.31 |
Enterprise value | About HK$375 million | Market cap − cash HK$331.3 million − FVPL HK$18.1 million + debt HK$4.8 million |
P/E, FY2025 reported | 7.9x | EPS 29.3 cents |
P/E, trailing twelve months to June 2026 | 7.3x | TTM profit HK$99.0 million (H2 2025 HK$51.6 million + H1 2026 HK$47.4 million) |
P/E, FY2025 underlying | 7.5x | Underlying EPS 30.7 cents |
EV/EBITDA, FY2025 | 3.2x | EBITDA HK$118.1 million |
EV/Sales, FY2025 | 1.8x | Revenue HK$213.9 million |
P/B | 0.98x | NAV HK$2.36 at 30 June 2026 |
Dividend yield, FY2025 | 8.2% | 19.0 cents |
Dividend yield, trailing declared | 8.7% | 11.0 cents final+special FY2025 + 9.0 cents interim 2026 |
Components
| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim dividend incl. special interim (HK cents) | 2.8 | 2.3 | 8.5 | 9.5 | 8.0 |
Final dividend (HK cents) | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
Special final dividend (HK cents) | 1.8 | 3.0 | 8.2 | 6.7 | 7.2 |
Total DPS (HK cents) | 8.4 | 9.1 | 20.5 | 20.0 | 19.0 |
Payout on reported EPS (%) | 68.3 | 94.8 | 60.8 | 79.4 | 64.8 |
Payout on underlying EPS (%) | 74.3 | 70.5 | 53.7 | 60.2 | 61.9 |
Analyst Conclusions
Management guidance (H1 2026 Interim Results, August 2026)
Cautious. Management expects continued headwinds from geopolitical tensions, energy price volatility, tariffs and cautious consumers. It considers the China improvement encouraging but uncertain in durability, expects core product sales to fluctuate modestly, expects new products and centenary campaigns to support demand, anticipates the deferred Philippine orders in H2 2026, and expects US orders to resume, keeping full-year North American revenue broadly stable. No quantitative guidance is given.
Consensus growth expectations
Not available — no broker coverage.
Bull case
-
Earnings have bottomed and are turning: H1 2026 revenue +6.7%, healthcare segment profit +14.7% and margin up to 64.2%; deferred Philippine and US orders should add to H2 2026, and Macau has normalised.
-
Deep value with downside protection: EV of about HK$375 million is only 3.2x FY2025 EBITDA; cash and securities of about HK$350 million cover roughly half the market cap, the stock trades near book, and the dividend yield exceeds 8%.
-
Centenary plus digital catalysts: The 2027 centenary campaign, two new product launches and maturing e-commerce and KOL programmes could re-rate a brand starting from an online base below 3% of sales.
Bear case
-
Structural brand erosion: China healthcare revenue fell 26.7% from FY2023 to FY2025; the core consumer is ageing and competitors and online-native brands are capturing younger buyers, while the company spends only about HK$10 million a year on advertising.
-
Concentration and fragility: Five distributors control about 75% of healthcare revenue, and H1 2026 showed how a single supplier delay, licence renewal or tariff decision can erase a region's sales.
-
Capital trapped in low-return assets and governance drag: Falling deposit rates are eroding treasury income, Hong Kong property continues to lose value (HK$93 million OCI deficits in two years), and a family-controlled board with no buybacks and no growth M&A limits the path to unlocking value.
Catalysts and monitorables (next 12 months)
| Monitorable | Timing | What to watch |
|---|---|---|
| Interim dividend payment | 4 Dec 2026 | Confirms payout |
| Thailand licence renewal and packaging changes | Q4 2026 | Distributor restocking or further destocking |
| US distributor order resumption | H2 2026 | Whether North America revenue is "broadly stable" for FY2026 |
| Philippine deferred shipments | H2 2026 | Southeast Asia recovery |
| Roll-On and GoodDay launches | 2026–2027 | Launch timing and early traction |
| Centenary campaign | 2,027 | Brand reach; advertising spend level |
| FY2026 annual results | Late March 2027 | Healthcare growth, margin, special dividend |
| Year-end property valuations | Dec 2026 | Hong Kong office values; further OCI deficits |
| Interest rates | Ongoing | Treasury income trajectory |
| Succession and governance | Ongoing | Any CEO succession plan; role of Gavin/Gary Gan; board refresh |
| Capital allocation | Ongoing | Any buyback, larger special dividend or acquisition |
Analyst verdict
Pak Fah Yeow International is a high-quality franchise housed inside an under-optimised holding company. The economics of the Hoe Hin White Flower business are genuinely excellent: a near-century-old brand earning segment margins near 60%, requiring negligible capital expenditure and generating cash far in excess of what the business can absorb. That cash has accumulated into roughly HK$350 million of deposits and securities alongside an HK$228 million property portfolio, so that the market effectively values the operating franchise at only about three times EBITDA.
The past three years have tested the franchise. The 2023 reopening boom flattered results, and the subsequent normalisation revealed concentration risks — dependence on China, on five distributors and on licence and supply-chain events — that the company is only beginning to address. Encouragingly, the first half of 2026 marked a return to growth with expanding margins, and management is finally investing in the channels where the next generation of consumers shops: Douyin, Xiaohongshu, KOLs and cross-border e-commerce. The centenary in 2027 and two new product formats give the brand its best opportunity in years to reach younger buyers.
The case against is structural rather than financial. A single traditional formula with an ageing consumer base faces gradual erosion, advertising spend remains modest, governance is family-dominated with a combined Chairman/CEO aged about 80, and there is no visible plan to redeploy surplus capital through buybacks or brand acquisitions. Property revaluations will continue to cloud reported earnings.
The key swing factors over the next twelve months are the durability of China's recovery, resolution of US tariff-related ordering, and evidence that the June 2026 succession step translates into a more dynamic capital-allocation strategy.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Board tenure / key dates | Background | Age (est.) |
|---|---|---|---|---|
Gan Wee Sean (顏為善) | Executive Director, Chairman and CEO; Remuneration Committee member | ED since 8 Oct 1991; acting CEO 21 Apr 2008; CEO since 1 Sep 2011 | Grandson of founder Gan Geok Eng; born Penang 1946; studied management in the UK; joined HK HQ in 1971; led the 1991 restructuring and listing. Fellow of the Institute of Chartered Secretaries and Administrators and of the Chartered Institute of Marketing; former chairman of the Chung Sing Benevolent Society (1987–1990) and of the Malaysian Association in Hong Kong (1987–1989) | About 80 (born 1946) |
Gan Fock Wai, Stephen (顏福偉) | Executive Director; Remuneration Committee member | ED for 20+ years; was CEO around 2005–2006 | Family member; director of Gan's Enterprises Limited, a substantial shareholder (per 2006 report) | About 65 (aged 45 in 2006) |
Gan Cheng Hooi, Gavin (顏清輝) | Executive Director | — | Son of Gan Wee Sean; now a co-owner of Hexagan Enterprises following the June 2026 transfer | — |
Gan Fook Yin, Anita (顏福燕) | Non-executive Director; Nomination Committee member | Nomination Committee since Dec 2023 | Family member | — |
Leung Man Chiu, Lawrence (梁文釗) | Independent Non-executive Director; Chairman of Audit, Nomination and Remuneration Committees | — | — | — |
Chan Chi Chung, Simon (陳志冲) | INED; member of all three committees | Joined 2022 | Consultant at a leading Hong Kong law firm with broad legal-sector experience (FY2022 Chairman's Statement) | — |
Dell'Orto Renato | INED; member of all three committees | Joined 2022 | Extensive experience in healthcare-sector supply chain management and market expansion (FY2022 Chairman's Statement) | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Director | Fees | Salary and benefits | Bonus | Retirement | Total FY2023 |
|---|---|---|---|---|---|
Gan Wee Sean (Chair/CEO) | 48 | 6,565 | 1,234 | 28 | 7,875 |
Gan Fock Wai, Stephen (ED) | 48 | 4,521 | 1,186 | 599 | 6,354 |
Gan Cheng Hooi, Gavin (ED) | 156 | 1,485 | 476 | 18 | 2,135 |
Gan Fook Yin, Anita (NED) | 151 | 0 | 0 | 0 | 151 |
Leung Man Chiu, Lawrence (INED) | 151 | 0 | 0 | 0 | 151 |
Chan Chi Chung, Simon (INED) | 151 | 0 | 0 | 0 | 151 |
Dell'Orto Renato (INED) | 151 | 0 | 0 | 0 | 151 |
Governance Overview
| Metric | Value |
|---|---|
Board size | 7 |
Executive directors | 3 (all Gan family) |
Non-executive (non-independent) | 1 (Gan family) |
Independent non-executive | 3 (43%) — meets the HKEX one-third minimum |
Family directors | 4 of 7 (57%) |
Women on board | 1 of 7 (14%) |
Chair/CEO separation | No — combined since 2011; disclosed deviation from CG Code provision C.2.1 |
Audit Committee | 3 INEDs; meets at least twice a year |
Committee chairs | One INED (Leung) chairs all three committees |
Major Shareholders
| Holder | Shares (M) | % | Source |
|---|---|---|---|
Hexagan Enterprises Limited (now owned by the four children of Gan Wee Sean: Gary Gan, Gavin Gan and two sisters) | 65.32 | 20.96 | Voluntary announcement, 30 Jun 2026 |
Gan Wee Sean (direct) | 27.21 | 8.73 | Same |
Madam Khoo Phaik Gim (spouse) | 2.38 | 0.76 | Same |
Gan Family Group subtotal | 94.91 | 30.46 | Same |
Competitive Landscape
Key Competitors
| Competitor | Owner | Key brands | Markets | Notes |
|---|---|---|---|---|
Haw Par Corporation (SGX: H02) | Listed, Singapore | Tiger Balm, Kwan Loong | 100+ countries; ASEAN core | Closest listed peer; similar holding-company structure with large investment portfolio |
Kwan Loong Medicated Oil | Haw Par | Kwan Loong | Singapore, Malaysia, Hong Kong | Direct medicated-oil rival; part of Haw Par Healthcare segment |
Axe Brand Universal Oil | Leung Kai Fook Medical Co. | Axe Brand | Hong Kong, China, SEA | Direct medicated-oil rival |
Eagle Brand Medicated Oil | Borden Company (Singapore; private) | Eagle Brand (green oil) | SEA, Hong Kong | Direct rival |
Lion King Oil | — | Lion King | Hong Kong | Direct rival in HK |
Zihua Embrocation | — | Zihua | Hong Kong | Positioned for consumers averse to pungent smells — competes with Fuzai 239 |
Po Sum On | Po Sum On Medicine Factory (Hong Kong; private) | Po Sum On oil | Hong Kong, overseas Chinese | Direct rival |
Wong To Yick Wood Lock Medicated Balm | Hong Kong (private) | Wood Lock oil | Hong Kong, China | Pain-relief oil rival |
Mentholatum | Rohto Pharmaceutical (Japan, listed) | Mentholatum ointments | Asia | Adjacent topical category |
Salonpas | Hisamitsu Pharmaceutical (Japan, listed) | Salonpas patches and sprays | Asia, US | Adjacent topical analgesic category |
Zheng Gu Shui | Guangxi Yulin Pharmaceutical (China) | Zheng Gu Shui | China, overseas Chinese | Traditional Chinese topical analgesic |
Mainland "feng you jing" producers | Various Chinese manufacturers | Generic medicated oils | Mainland China | Low-price competition |
Peer Comparison FY2025
| Metric | Pak Fah Yeow FY2025 | Haw Par FY2025 |
|---|---|---|
Group revenue | HK$213.9 million | S$230.0 million (approx. HK$1.4 billion) |
Healthcare revenue | HK$197.3 million | S$210.4 million per Haw Par Annual Report 2025 (one third-party source cites S$240.5 million — discrepancy noted; S$210.4 million is consistent with group revenue of S$230.0 million) |
Healthcare revenue growth | -9.2% | -7% |
Healthcare segment profit | HK$116.8 million | S$67.1 million (+7%) |
Healthcare segment margin | 59.2% | About 32% (S$67.1 million / S$210.4 million) |
Net profit | HK$91.3 million | S$265.5 million (+16.3%, driven by dividend income) |
Net cash | About HK$326 million | About S$791 million cash |



